Overview

This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

Eligibility

Inclusion Criteria:

• Adult patients between 50 and 75 years old
• Subjects at intermediate to high risk for ASCVD
• Asymptomatic patients without cardiac chest pain
• Evidence of atherosclerosis on baseline CCTA

Exclusion Criteria:

• Renal insufficiency, defined as eGFR < 30 ml/min
• History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke)
• Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy
• Change in lipid lowering therapy in the last 6 months
• Use of more than two antihypertensive agents
• No coronary atherosclerosis at baseline imaging
• Active malignancy requiring treatment
• Atrial fibrillation
• Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
• Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.